Engineering CAR T cells to activate a bodily response to solid tumors Engineering CAR T cells to activate a bodily response to solid tumors A new Penn study shows that CAR T cells expressing RN7SL1, a naturally occurring RNA, can activate the body’s natural immune cells against difficult-to-treat cancers.
CAR T cells engineered to deliver RNA to enhance immunotherapy response Penn In the News Technology Networks CAR T cells engineered to deliver RNA to enhance immunotherapy response Andy J. Minn of the Perelman School of Medicine explains how Chimeric antigen receptor T cells typically are like lone soldiers without backup. Clarifying T cell ‘exhaustion’ Clarifying T cell ‘exhaustion’ T cells, which are among the most powerful weapons in the immune systems of humans and other vertebrates, remain substantially programmed to stay exhausted even many weeks after exposure to a virus ended. New cell therapy shows potential against solid tumors with KRAS mutations New cell therapy shows potential against solid tumors with KRAS mutations The new technology for cellular immunotherapy shows promising anti-tumor activity in the lab against hard-to-treat cancers driven the KRAS mutation. Low on antibodies, blood cancer patients can fight off COVID-19 with T cells Low on antibodies, blood cancer patients can fight off COVID-19 with T cells T cells can step up to do the job when antibodies are depleted, suggests a new Penn Medicine study of blood cancer patients with COVID-19. Cancer cell therapy pioneer Carl June receives the Sanford Lorraine Cross Award Cancer cell therapy pioneer Carl June receives the Sanford Lorraine Cross Award The Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine in the Perelman School of Medicine and director of the Center for Cellular Immunotherapies at Penn’s Abramson Cancer Center received the award for his work in developing chimeric antigen receptor (CAR) T cell therapy. Immune response in some children may influence COVID treatments for adults Immune response in some children may influence COVID treatments for adults A joint study from researchers at Penn and the Children’s Hospital of Philadelphia shows that T cell activation in children with multisystem inflammatory syndrome is more similar to adults with severe COVID-19. Microbial transplants require key T cells for success Microbial transplants require key T cells for success Findings that certain immune cells are needed for fecal microbiota transplant success against C. difficile infections may be a clue to making this promising treatment work more broadly. Five years later: CAR T therapy shows long-lasting remissions in non-Hodgkin lymphomas Five years later: CAR T therapy shows long-lasting remissions in non-Hodgkin lymphomas Findings represent the longest follow-up data to date for a personalized cellular therapy approved by the FDA for the treatment of aggressive lymphomas.
Clarifying T cell ‘exhaustion’ Clarifying T cell ‘exhaustion’ T cells, which are among the most powerful weapons in the immune systems of humans and other vertebrates, remain substantially programmed to stay exhausted even many weeks after exposure to a virus ended.
New cell therapy shows potential against solid tumors with KRAS mutations New cell therapy shows potential against solid tumors with KRAS mutations The new technology for cellular immunotherapy shows promising anti-tumor activity in the lab against hard-to-treat cancers driven the KRAS mutation.
Low on antibodies, blood cancer patients can fight off COVID-19 with T cells Low on antibodies, blood cancer patients can fight off COVID-19 with T cells T cells can step up to do the job when antibodies are depleted, suggests a new Penn Medicine study of blood cancer patients with COVID-19.
Cancer cell therapy pioneer Carl June receives the Sanford Lorraine Cross Award Cancer cell therapy pioneer Carl June receives the Sanford Lorraine Cross Award The Richard W. Vague Professor in Immunotherapy in the department of Pathology and Laboratory Medicine in the Perelman School of Medicine and director of the Center for Cellular Immunotherapies at Penn’s Abramson Cancer Center received the award for his work in developing chimeric antigen receptor (CAR) T cell therapy.
Immune response in some children may influence COVID treatments for adults Immune response in some children may influence COVID treatments for adults A joint study from researchers at Penn and the Children’s Hospital of Philadelphia shows that T cell activation in children with multisystem inflammatory syndrome is more similar to adults with severe COVID-19.
Microbial transplants require key T cells for success Microbial transplants require key T cells for success Findings that certain immune cells are needed for fecal microbiota transplant success against C. difficile infections may be a clue to making this promising treatment work more broadly.
Five years later: CAR T therapy shows long-lasting remissions in non-Hodgkin lymphomas Five years later: CAR T therapy shows long-lasting remissions in non-Hodgkin lymphomas Findings represent the longest follow-up data to date for a personalized cellular therapy approved by the FDA for the treatment of aggressive lymphomas.